

# Programme: Horizon Europe

Project Start Date: 01/07/2022

Project Duration: 48 months

**Project ID:** 101057438

**Call for proposals:** HORIZON-HLTH-2021-TOOL-06

**Coordinator:** CHARITE -  
UNIVERSITAETSMEDIZIN BERLIN

**Project participants:** 12

**Project website:** <https://www.genetiga-horizon.eu/>

**Project value:** 6,393,734.00€

**Genos contribution:** 596,875.00€



Co-funded by  
the European Union

## GeneTiga

Gene-edited T cells combating IgA Nephropathy. A blueprint approach for safe & efficient genome editing of T cells to sustainably combat several immune diseases and cancers related to B-cell pathology

There is an unprecedented increase in chronic diseases due to immune imbalance for which there are limited treatment options. The EU-funded geneTIGA is developing a safe and efficient cell therapy based on genome-edited T cells to sustainably combat IgA nephropathy (IgAN), one of the most common causes of endstage renal disease. As an IgA disease, this cell therapy approach can form the blueprint for other IgA diseases including IgA myeloma, IgA related coeliac disease and rheumatoid arthritis, as well as other Ig diseases. Thus, geneTIGA researchers anticipate the delivery of a 'living drug' to treat IgAN and other IgA-associated diseases for entry to first-in-human clinical trials.